Kolorektal orjinli senkron peritoneal karsinomatozis tedavisinde sitoredüktif cerrahi ve intraperitoneal kemoterapi uygulaması

Sitoredüktif cerrahi SC ve hipertermik intraperitoneal kemoterapinin HİPEK temel amacı makroskopik ve mikroskobik malign peritoneal hastalığı tedavi etmektir. Sitoredüktif cerrahi ile makroskopik, mümkünse aynı operasyonda yapılan hipertermik intraperitoneal kemoterapi ile hücre boyutundaki mikroskobik peritoneal hastalık tedavi edilmektedir. SC+HİPEK peritoneal pseudomiksoma, peritoneal mezotelyoma ve limitli peritoneal yayılımı olan kolorektal kanserlerde standart tedavi yaklaşımıdır. Bu vaka sunumunun amacı SC+HİPEK operasyonu geçirmiş, senkron peritoneal yayılımı olan kolorektal kanserli 65 yaşındaki erkek hastanın değerlendirilmesidir. Hasta postoperatif dönemde 7 ay boyunca takip edildi, kanser lehine bulguya rastlanmadı. Hastanın cerrahi sonrasında işgücü ve yaşam kalitesi kaybı olmadı. Hasta halen takip altındadır.

Cytoreductive surgery and intraperitoneal chemoteraphy treatment of colorectal originated synchron peritoneal carcinomatosis

The main purpose of cytoreductive surgery and intraperitoneal chemotherapy is to treat macroscopic malignant peritoneal disease with cytoreductive surgery CS and, to treat in the same operation if it is possible cell-sized peritoneal microscopic disease with intraperitoneal chemotherapy HIPEC . CS+HIPEC is the standart of care for the treatment of peritoneal pseudomyxomas, peritoneal mesotheliomas and colorectal cancers with limited peritoneal extension. The aim of this case report is to present a 65 years old, male patient with colorectal cancer and synchron peritoneal carcinomatosis, who underwent CS+HIPEC. The patient was followed up for 7 months in postoperative period, no evidence of malignancy was found. There was no loss of labor. Patient’s quality of life was improved. The patient is still under follow-up.

___

  • 1. C. Cao, T.D. Yan, D. L. Morris. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorektal origin. Ann. Surg. Oncol. 16 2009;2152-2165
  • 2. Spratt JS, Adcock RA, Muscovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256-260
  • 3. Sugarbaker PH, Cunliffe WJ, Beliveau JF, et al. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treatment 1988;1:66-79
  • 4. D. Elias, D. Goere, F. Dumont, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. European Journal of Cancer 2014;50:332-340
  • 5. Sugarbaker PH. It’s what the surgeon doesn’t see kills the patient. J Nippon Med Sch 2000;67:5-8
  • 6. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29-42
  • 7. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-374
  • 8. Los G, Mutsaers PH, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384
  • 9. Chao-Qun Huang, Yao Min, Shu-Yi Wang, at al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017;8:55657-55683
  • 10. Chi-Jung Huang, Jeng-Kai Jiang, Shih-Ching Cahng, at al. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine 2016;95:47
  • 11. D. Elias, A. Mariani, A.-S. Cloutier, at al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. EJSO 2014;40:1467-1473